{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:24:08Z","timestamp":1788791048278,"version":"build-2803163510"},"reference-count":139,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T00:00:00Z","timestamp":1651881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jhepr.2022.100498","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T22:51:07Z","timestamp":1652482267000},"page":"100498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity"],"prefix":"10.1016","volume":"4","author":[{"given":"Shirley","family":"Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisling","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodor","family":"Stanescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issa","family":"Mohamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hosni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jhepr.2022.100498_bib2","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.jhepr.2022.100498_bib3","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015","volume":"3","author":"Akinyemiju","year":"2017","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.jhepr.2022.100498_bib4","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/hep.29498","article-title":"Projections of primary liver cancer to 2030 in 30 countries worldwide","volume":"67","author":"Valery","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/13651820410024058","article-title":"Staging systems in hepatocellular carcinoma","volume":"7","author":"Pons","year":"2005","journal-title":"HPB (Oxford)"},{"issue":"2","key":"10.1016\/j.jhepr.2022.100498_bib6","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.jhepr.2022.100498_bib7","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S2468-1253(20)30182-5","article-title":"Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective","volume":"5","author":"Barry","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jhepr.2022.100498_bib8","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1148\/radiol.12111550","article-title":"Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib","volume":"263","author":"Pinter","year":"2012","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.jhepr.2022.100498_bib9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3748\/wjg.v26.i4.393","article-title":"Indications of external radiotherapy for hepatocellular carcinoma from updated clinical guidelines: diverse global viewpoints","volume":"26","author":"Park","year":"2020","journal-title":"World J Gastroenterol"},{"issue":"8","key":"10.1016\/j.jhepr.2022.100498_bib10","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1053\/j.gastro.2017.02.040","article-title":"Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality","volume":"152","author":"Serper","year":"2017","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jhepr.2022.100498_bib11","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/lt.21368","article-title":"Liver transplantation in patients with hepatocellular carcinoma across Milan criteria","volume":"14","author":"Herrero","year":"2008","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jhepr.2022.100498_bib12","article-title":"Ten-year survival and recurrence of hepatocellular cancer","volume":"5","author":"Sempokuya","year":"2019","journal-title":"Hepatoma Res"},{"issue":"4","key":"10.1016\/j.jhepr.2022.100498_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001624","article-title":"Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis","volume":"11","author":"Singal","year":"2014","journal-title":"PLoS Med"},{"issue":"7","key":"10.1016\/j.jhepr.2022.100498_bib14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00432-004-0552-0","article-title":"Randomized controlled trial of screening for hepatocellular carcinoma","volume":"130","author":"Zhang","year":"2004","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"6","key":"10.1016\/j.jhepr.2022.100498_bib15","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/0360-3016(89)90530-0","article-title":"194 hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response: a Radiation Therapy Oncology Group Study","volume":"17","author":"Stillwagon","year":"1989","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.jhepr.2022.100498_bib16","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3857\/roj.2016.01970","article-title":"Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines","volume":"34","author":"Rim","year":"2016","journal-title":"Radiat Oncol J"},{"issue":"4","key":"10.1016\/j.jhepr.2022.100498_bib17","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.semradonc.2005.04.005","article-title":"Partial volume tolerance of the liver to radiation","volume":"15","author":"Dawson","year":"2005","journal-title":"Semin Radiat Oncol"},{"issue":"10","key":"10.1016\/j.jhepr.2022.100498_bib18","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1046\/j.1440-1746.1999.01994.x","article-title":"A\u00a0pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma","volume":"14","author":"Cheng","year":"1999","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.jhepr.2022.100498_bib19","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/jjco\/hyh089","article-title":"Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization","volume":"34","author":"Liu","year":"2004","journal-title":"Jpn J Clin Oncol"},{"issue":"21","key":"10.1016\/j.jhepr.2022.100498_bib20","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1002\/cncr.24552","article-title":"Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma","volume":"115","author":"McIntosh","year":"2009","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jhepr.2022.100498_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5009\/gnl.2013.7.3.343","article-title":"Treatment outcomes of helical intensity-modulated radiotherapy for unresectable hepatocellular carcinoma","volume":"7","author":"Kong","year":"2013","journal-title":"Gut Liver"},{"issue":"34","key":"10.1016\/j.jhepr.2022.100498_bib22","doi-asserted-by":"crossref","first-page":"8739","DOI":"10.1200\/JCO.2005.01.5354","article-title":"Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies","volume":"23","author":"Ben-Josef","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/B:JORA.0000010880.40483.c4","article-title":"Radiosurgery for tumors in the body: clinical experience using a new method","volume":"1","author":"Blomgren","year":"1998","journal-title":"J\u00a0Radiosurgery"},{"issue":"2","key":"10.1016\/j.jhepr.2022.100498_bib24","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijrobp.2013.07.022","article-title":"The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?","volume":"88","author":"Brown","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.jhepr.2022.100498_bib25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1667\/RR2773.1","article-title":"Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS)","volume":"177","author":"Park","year":"2012","journal-title":"Radiat Res"},{"issue":"2577","key":"10.1016\/j.jhepr.2022.100498_bib26","article-title":"Combinational immunotherapy for hepatocellular carcinoma: radiotherapy, immune checkpoint blockade and beyond","volume":"11","author":"Lee","year":"2020","journal-title":"Front Immunol"},{"issue":"21","key":"10.1016\/j.jhepr.2022.100498_bib27","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1002\/cncr.27533","article-title":"Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization","volume":"118","author":"Kang","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.jhepr.2022.100498_bib28","doi-asserted-by":"crossref","first-page":"734","DOI":"10.21037\/jgo.2018.05.01","article-title":"Stereotactic body radiation therapy following transarterial chemoembolization for unresectable hepatocellular carcinoma","volume":"9","author":"Buckstein","year":"2018","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"8","key":"10.1016\/j.jhepr.2022.100498_bib29","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1080\/0284186X.2020.1741679","article-title":"Local control by salvage stereotactic body radiotherapy for recurrent\/residual hepatocellular carcinoma after other local therapies","volume":"59","author":"Kibe","year":"2020","journal-title":"Acta Oncologica"},{"issue":"3","key":"10.1016\/j.jhepr.2022.100498_bib30","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jhep.2020.09.026","article-title":"Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial","volume":"74","author":"Kim","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.jhepr.2022.100498_bib31","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3350\/cmh.2020.0038","article-title":"Stereotactic body radiation therapy for small (\u2264 5 cm) hepatocellular carcinoma not amenable to curative treatment: results of a single-arm, phase II clinical trial","volume":"26","author":"Yoon","year":"2020","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib32","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijrobp.2019.12.004","article-title":"Curative irradiation treatment of hepatocellular carcinoma: a multicenter phase 2 trial","volume":"107","author":"Durand-Labrunie","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.jhepr.2022.100498_bib33","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/cncr.32502","article-title":"A\u00a0phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: safety and efficacy","volume":"126","author":"Jang","year":"2020","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.jhepr.2022.100498_bib34","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1111\/jgh.15011","article-title":"Clinical outcomes of stereotactic body radiation therapy for small hepatocellular carcinoma","volume":"35","author":"Park","year":"2020","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100498_bib35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2020.04.024","article-title":"Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion","volume":"134","author":"Mathew","year":"2020","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.jhepr.2022.100498_bib36","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.dld.2018.11.004","article-title":"Phase I\/II trial of helical IMRT-based stereotactic body radiotherapy for hepatocellular carcinoma","volume":"51","author":"Kim","year":"2019","journal-title":"Dig Liver Dis"},{"issue":"6","key":"10.1016\/j.jhepr.2022.100498_bib37","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1002\/hep.30591","article-title":"Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation: a propensity score analysis","volume":"69","author":"Hara","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2017.2303","article-title":"Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: a phase 2 clinical trial","volume":"4","author":"Feng","year":"2018","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1016\/j.jhepr.2022.100498_bib39","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1002\/cncr.30008","article-title":"Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation","volume":"122","author":"Takeda","year":"2016","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jhepr.2022.100498_bib40","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1016\/j.prro.2015.02.007","article-title":"Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy","volume":"5","author":"Lasley","year":"2015","journal-title":"Pract Radiat Oncol"},{"issue":"7","key":"10.1016\/j.jhepr.2022.100498_bib41","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00432-015-1929-y","article-title":"The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT)","volume":"141","author":"Scorsetti","year":"2015","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"13","key":"10.1016\/j.jhepr.2022.100498_bib42","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","article-title":"Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma","volume":"31","author":"Bujold","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.jhepr.2022.100498_bib43","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/j.ijrobp.2011.04.011","article-title":"Stereotactic body radiotherapy for primary hepatocellular carcinoma","volume":"81","author":"Andolino","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jhepr.2022.100498_bib44","series-title":"Evidence-based nursing care guidelines-E-book: medical-surgical interventions","author":"Ackley","year":"2007"},{"issue":"5","key":"10.1016\/j.jhepr.2022.100498_bib45","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2017.5847","article-title":"Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial","volume":"4","author":"Yoon","year":"2018","journal-title":"JAMA Oncol"},{"issue":"24","key":"10.1016\/j.jhepr.2022.100498_bib46","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1200\/JCO.18.02184","article-title":"Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study","volume":"37","author":"Wei","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.jhepr.2022.100498_bib47","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhepr.2022.100498_bib48","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2021.12.029","article-title":"BCLC 2022 update: important advances, but missing external beam radiotherapy","volume":"76","author":"Hallemeier","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib49","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.prro.2021.09.004","article-title":"External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline","volume":"12","author":"Apisarnthanarax","year":"2022","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib50","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib51","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/hep.29485","article-title":"Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis","volume":"67","author":"Kulik","year":"2018","journal-title":"Hepatology"},{"issue":"5 Suppl 1","key":"10.1016\/j.jhepr.2022.100498_bib52","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1053\/j.gastro.2004.09.033","article-title":"High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial","volume":"127","author":"Bush","year":"2004","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jhepr.2022.100498_bib53","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.ijrobp.2011.08.032","article-title":"Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation","volume":"83","author":"Katz","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.jhepr.2022.100498_bib54","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1432-2277.2009.00980.x","article-title":"Radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma","volume":"23","author":"Sandroussi","year":"2010","journal-title":"Transpl Int"},{"issue":"8","key":"10.1016\/j.jhepr.2022.100498_bib55","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/lt.23439","article-title":"Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation","volume":"18","author":"O'Connor","year":"2012","journal-title":"Liver Transplant"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib56","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.adro.2015.12.003","article-title":"Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma","volume":"1","author":"Mohamed","year":"2016","journal-title":"Adv Radiat Oncol"},{"issue":"4_suppl","key":"10.1016\/j.jhepr.2022.100498_bib57","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1200\/JCO.2017.35.4_suppl.223","article-title":"A\u00a0randomized phase II study of individualized stereotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) with DEBDOX beads as a bridge to transplant in hepatocellular carcinoma (HCC)","volume":"35","author":"Nugent","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jhepr.2022.100498_bib58","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1200\/JCO.2020.38.15_suppl.4586","article-title":"A\u00a0randomized phase II feasibility study of individualized stereotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) with DEBDOX beads as a bridge to transplant in hepatocellular carcinoma (HCC)","volume":"38","author":"Nugent","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib59","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ijrobp.2016.02.027","article-title":"Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis","volume":"95","author":"Bush","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib60","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jhep.2017.02.022","article-title":"Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis","volume":"67","author":"Sapisochin","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jhepr.2022.100498_bib61","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/01.sla.0000201480.65519.b8","article-title":"A\u00a0prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma","volume":"243","author":"Chen","year":"2006","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.jhepr.2022.100498_bib62","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1440-1746.2009.06125.x","article-title":"Percutaneous radiofrequency ablation as first-line treatment for small hepatocellular carcinoma: results and prognostic factors on long-term follow up","volume":"25","author":"Waki","year":"2010","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100498_bib63","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/JHC.S284403","article-title":"Current understanding of ablative radiation therapy in hepatocellular carcinoma","volume":"8","author":"Mathew","year":"2021","journal-title":"J\u00a0Hepatocell Carcinoma"},{"issue":"5","key":"10.1016\/j.jhepr.2022.100498_bib64","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/1754-9485.12754","article-title":"Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: an analysis of SEER-Medicare","volume":"62","author":"Parikh","year":"2018","journal-title":"J\u00a0Med Imaging Radiat Oncol"},{"issue":"5","key":"10.1016\/j.jhepr.2022.100498_bib65","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1200\/JCO.2015.61.4925","article-title":"Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma","volume":"34","author":"Wahl","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.jhepr.2022.100498_bib66","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.2017.75.3228","article-title":"Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: analysis of the national cancer database","volume":"36","author":"Rajyaguru","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhepr.2022.100498_bib67","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3389\/fonc.2020.00347","article-title":"Stereotactic body radiation therapy vs. transarterial chemoembolization in inoperable barcelona clinic liver cancer stage a hepatocellular carcinoma: a retrospective, propensity-matched analysis","volume":"10","author":"Su","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhepr.2022.100498_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01639","article-title":"Stereotactic body radiotherapy vs. radiofrequency ablation in the treatment of hepatocellular carcinoma: a meta-analysis","volume":"10","author":"Pan","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhepr.2022.100498_bib69","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.radonc.2019.12.004","article-title":"Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: meta-analyses and a systematic review","volume":"145","author":"Lee","year":"2020","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib70","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/02656736.2020.1843719","article-title":"Stereotactic body radiotherapy versus radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"37","author":"Wang","year":"2020","journal-title":"Int J Hyperthermia"},{"issue":"3","key":"10.1016\/j.jhepr.2022.100498_bib71","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.radonc.2014.05.002","article-title":"Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma","volume":"111","author":"Culleton","year":"2014","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib72","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijrobp.2017.12.288","article-title":"Local control after stereotactic body radiation therapy for liver tumors","volume":"110","author":"Ohri","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib73","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13014-021-01778-6","article-title":"Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study","volume":"16","author":"Su","year":"2021","journal-title":"Radiat Oncol"},{"issue":"2","key":"10.1016\/j.jhepr.2022.100498_bib74","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib75","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijrobp.2017.09.001","article-title":"Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma","volume":"100","author":"Sapir","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib76","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1186\/s12885-018-4696-8","article-title":"Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis","volume":"18","author":"Bettinger","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-016-2894-9","article-title":"Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma> 5 cm","volume":"16","author":"Su","year":"2016","journal-title":"BMC cancer"},{"issue":"5\u20136","key":"10.1016\/j.jhepr.2022.100498_bib78","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000505739","article-title":"Stereotactic body radiotherapy combined with transcatheter arterial chemoembolization versus stereotactic body radiotherapy alone as the first-line treatment for unresectable hepatocellular carcinoma: a meta-analysis and systematic review","volume":"64","author":"Zhao","year":"2019","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jhepr.2022.100498_bib79","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.radonc.2020.11.033","article-title":"Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion","volume":"156","author":"Munoz-Schuffenegger","year":"2021","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.jhepr.2022.100498_bib80","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000490260","article-title":"Stereotactic body radiation therapy as an alternative treatment for patients with hepatocellular carcinoma compared to sorafenib: a propensity score analysis","volume":"8","author":"Bettinger","year":"2019","journal-title":"Liver Cancer"},{"issue":"7","key":"10.1016\/j.jhepr.2022.100498_bib81","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/0360-3016(87)90045-9","article-title":"A\u00a0comparison of misonidazole sensitized radiation therapy to radiation therapy alone for the palliation of hepatic metastases: results of a radiation therapy oncology group randomized prospective trial","volume":"13","author":"Leibel","year":"1987","journal-title":"Int J Radiat Oncology\u2217Biology\u2217Physics"},{"issue":"5","key":"10.1016\/j.jhepr.2022.100498_bib82","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/0360-3016(81)90370-9","article-title":"The palliation of hepatic metastases: results of the Radiation Therapy Oncology Group pilot study","volume":"7","author":"Borgelt","year":"1981","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"31","key":"10.1016\/j.jhepr.2022.100498_bib83","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1200\/JCO.2013.49.9202","article-title":"Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases","volume":"31","author":"Soliman","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.jhepr.2022.100498_bib84","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.semradonc.2018.06.007","article-title":"Radiation-induced liver disease and modern radiotherapy","volume":"28","author":"Koay","year":"2018","journal-title":"Semin Radiat Oncol"},{"issue":"5","key":"10.1016\/j.jhepr.2022.100498_bib85","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ijrobp.2017.01.221","article-title":"Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma","volume":"97","author":"Velec","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib86","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1186\/s12885-019-6063-9","article-title":"Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (\u22645 cm)","volume":"19","author":"Sun","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib87","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.radonc.2016.10.024","article-title":"Central liver toxicity after SBRT: an expanded analysis and predictive nomogram","volume":"122","author":"Toesca","year":"2017","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.jhepr.2022.100498_bib88","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.ijrobp.2012.09.012","article-title":"Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system","volume":"85","author":"Eriguchi","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.jhepr.2022.100498_bib89","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ijrobp.2010.03.020","article-title":"Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver","volume":"80","author":"Andolino","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.jhepr.2022.100498_bib90","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/S1470-2045(20)30034-6","article-title":"MRI-guided adaptive radiotherapy for liver tumours: visualising the future","volume":"21","author":"Witt","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib91","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.adro.2018.08.005","article-title":"A\u00a0multi-institutional experience of MR-guided liver stereotactic body radiation therapy","volume":"4","author":"Rosenberg","year":"2019","journal-title":"Adv Radiat Oncol"},{"issue":"9","key":"10.1016\/j.jhepr.2022.100498_bib92","article-title":"Real-time magnetic resonance-guided liver stereotactic body radiation therapy: an institutional report using a magnetic resonance-linac system","volume":"11","author":"Feldman","year":"2019","journal-title":"Cureus"},{"issue":"7","key":"10.1016\/j.jhepr.2022.100498_bib93","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s00432-020-03480-8","article-title":"MRI-guided stereotactic radiation therapy for hepatocellular carcinoma: a feasible and safe innovative treatment approach","volume":"147","author":"Boldrini","year":"2021","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"5","key":"10.1016\/j.jhepr.2022.100498_bib94","article-title":"Implementation of stereotactic MRI-guided adaptive radiotherapy (SMART) for hepatobiliary and pancreatic cancers in the United Kingdom - fifty in five","volume":"13","author":"Gaya","year":"2021","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.jhepr.2022.100498_bib95","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.radonc.2017.11.032","article-title":"Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen","volume":"126","author":"Henke","year":"2018","journal-title":"Radiother Oncol"},{"issue":"28","key":"10.1016\/j.jhepr.2022.100498_bib96","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.3748\/wjg.v24.i28.3090","article-title":"Proton therapy for hepatocellular carcinoma: current knowledges and future perspectives","volume":"24","author":"Yoo","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.jhepr.2022.100498_bib97","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.ijrobp.2010.07.015","article-title":"Proton beam therapy for hepatocellular carcinoma: a comparison of three treatment protocols","volume":"81","author":"Mizumoto","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"13","key":"10.1016\/j.jhepr.2022.100498_bib98","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1002\/cncr.25809","article-title":"The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial","volume":"117","author":"Bush","year":"2011","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jhepr.2022.100498_bib99","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/cas.13145","article-title":"Long-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma","volume":"108","author":"Fukuda","year":"2017","journal-title":"Cancer Sci"},{"issue":"5","key":"10.1016\/j.jhepr.2022.100498_bib100","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2015.64.2710","article-title":"Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"34","author":"Hong","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"542","key":"10.1016\/j.jhepr.2022.100498_bib101","article-title":"Phase II study of hypofractionated proton beam therapy for hepatocellular carcinoma","volume":"10","author":"Kim","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib102","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijrobp.2019.01.076","article-title":"Protons versus photons for unresectable hepatocellular carcinoma: liver decompensation and overall survival","volume":"105","author":"Sanford","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.jhepr.2022.100498_bib103","article-title":"Intensity modulated proton therapy for hepatocellular carcinoma: initial clinical experience","volume":"6","author":"Bhangoo","year":"2021","journal-title":"Adv Radiat Oncol"},{"issue":"10","key":"10.1016\/j.jhepr.2022.100498_bib104","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s00432-018-2729-y","article-title":"Stereotactic body radiation therapy for centrally located hepatocellular carcinoma: outcomes and toxicities","volume":"144","author":"Lazarev","year":"2018","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib105","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1200\/JCO.2001.19.1.164","article-title":"Stereotactic single-dose radiation therapy of liver tumors: results of a phase I\/II trial","volume":"19","author":"Herfarth","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.jhepr.2022.100498_bib106","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ijrobp.2009.08.020","article-title":"Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies","volume":"78","author":"Goodman","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib107","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1245\/s10434-015-4579-z","article-title":"A\u00a0phase I dose-escalation trial of single-fraction stereotactic radiation therapy for liver metastases","volume":"23","author":"Meyer","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jhepr.2022.100498_bib108","first-page":"60","article-title":"The rationale for MR-only treatment\u00a0planning for external radiotherapy","volume":"18","author":"Jonsson","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.jhepr.2022.100498_bib109","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.phro.2020.09.009","article-title":"Clinical experience and workflow challenges with magnetic resonance-only radiation therapy simulation and planning for prostate cancer","volume":"16","author":"Tyagi","year":"2020","journal-title":"Phys Imaging Radiat Oncol"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib110","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13014-020-01513-7","article-title":"MR-PROTECT: Clinical feasibility of a prostate MRI-only radiotherapy treatment workflow and investigation of acceptance criteria","volume":"15","author":"Persson","year":"2020","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib111","doi-asserted-by":"crossref","DOI":"10.1088\/2057-1976\/ab6e1f","article-title":"Generation of abdominal synthetic CTs from 0.35T MR images using generative adversarial networks for MR-only liver radiotherapy","volume":"6","author":"Fu","year":"2020","journal-title":"Biomed Phys Eng Express"},{"issue":"1100","key":"10.1016\/j.jhepr.2022.100498_bib112","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20190067","article-title":"MRI-based treatment planning for liver stereotactic body radiotherapy: validation of a deep learning-based synthetic CT generation method","volume":"92","author":"Liu","year":"2019","journal-title":"Br J Radiol"},{"issue":"26","key":"10.1016\/j.jhepr.2022.100498_bib113","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.3748\/wjg.v26.i26.3720","article-title":"Intratumoral heterogeneity of hepatocellular carcinoma: from single-cell to population-based studies","volume":"26","author":"Zhang","year":"2020","journal-title":"World J Gastroenterol"},{"issue":"11","key":"10.1016\/j.jhepr.2022.100498_bib114","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112621","article-title":"The endless sources of hepatocellular carcinoma heterogeneity","volume":"13","author":"Barcena-Varela","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.jhepr.2022.100498_bib115","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3350\/cmh.2015.21.3.257","article-title":"Influence of P53 on the radiotherapy response of hepatocellular carcinoma","volume":"21","author":"Gomes","year":"2015","journal-title":"Clin Mol Hepatol"},{"issue":"5","key":"10.1016\/j.jhepr.2022.100498_bib116","first-page":"5733","article-title":"Effects of TACE combined with precise RT on p53 gene expression and prognosis of HCC patients","volume":"16","author":"Liu","year":"2018","journal-title":"Oncol Lett"},{"issue":"2","key":"10.1016\/j.jhepr.2022.100498_bib117","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.canlet.2011.10.012","article-title":"CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma","volume":"315","author":"Piao","year":"2012","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jhepr.2022.100498_bib118","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.radonc.2021.06.034","article-title":"Wnt\/\u03b2-catenin inhibitor ICG-001 enhances the antitumor efficacy of radiotherapy by increasing radiation-induced DNA damage and improving tumor immune microenvironment in hepatocellular carcinoma","volume":"162","author":"Huang","year":"2021","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib119","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41698-020-0124-z","article-title":"Association of pro-inflammatory soluble cytokine receptors early during hepatocellular carcinoma stereotactic radiotherapy with liver toxicity","volume":"4","author":"Ng","year":"2020","journal-title":"NPJ Precis Oncol"},{"issue":"3","key":"10.1016\/j.jhepr.2022.100498_bib120","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1148\/radiology.210.3.r99fe17617","article-title":"Diffusion coefficients in abdominal organs and hepatic lesions: evaluation with intravoxel incoherent motion echo-planar MR imaging","volume":"210","author":"Yamada","year":"1999","journal-title":"Radiology"},{"issue":"12","key":"10.1016\/j.jhepr.2022.100498_bib121","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.3748\/wjg.v20.i12.3125","article-title":"DCE-MRI in hepatocellular carcinoma-clinical and therapeutic image biomarker","volume":"20","author":"Chen","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib122","article-title":"A\u00a0study of the correlations between IVIM-DWI parameters and the histologic differentiation of hepatocellular carcinoma","volume":"11","author":"Zhou","year":"2021","journal-title":"Scientific Rep"},{"issue":"2944","key":"10.1016\/j.jhepr.2022.100498_bib123","article-title":"A\u00a0correlative study between IVIM-DWI parameters and the expression levels of Ang-2 and TKT in hepatocellular carcinoma","volume":"10","author":"Zheng","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhepr.2022.100498_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40644-016-0059-3","article-title":"Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study","volume":"16","author":"Shirota","year":"2016","journal-title":"Cancer Imaging"},{"issue":"3","key":"10.1016\/j.jhepr.2022.100498_bib125","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/jmri.25617","article-title":"ADC(total) ratio and D ratio derived from intravoxel incoherent motion early after TACE are independent predictors for survival in hepatocellular carcinoma","volume":"46","author":"Wu","year":"2017","journal-title":"J\u00a0Magn Reson Imaging"},{"issue":"8","key":"10.1016\/j.jhepr.2022.100498_bib126","article-title":"Dynamic contrast-enhanced and intravoxel incoherent motion MRI biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma","volume":"11","author":"Chen","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"4","key":"10.1016\/j.jhepr.2022.100498_bib127","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ejca.2011.11.036","article-title":"Radiomics: extracting more information from medical images using advanced feature analysis","volume":"48","author":"Lambin","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhepr.2022.100498_bib128","article-title":"Utility of radiomics for predicting patient survival in hepatocellular carcinoma with portal vein tumor thrombosis treated with stereotactic body radiotherapy","volume":"10","author":"Wu","year":"2020","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.jhepr.2022.100498_bib129","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/apt.16563","article-title":"Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma","volume":"54","author":"Harding-Theobald","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.jhepr.2022.100498_bib130","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1007\/s00066-020-01615-x","article-title":"Radiomics for liver tumours","volume":"196","author":"Dreher","year":"2020","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.jhepr.2022.100498_bib131","doi-asserted-by":"crossref","first-page":"S1109","DOI":"10.1016\/S0167-8140(19)32443-0","article-title":"EP-2023 Predictive value of delta-radiomics features extracted from MR Images in image-guided liver SBRT","volume":"133","author":"Dogan","year":"2019","journal-title":"Radiother Oncol"},{"issue":"20","key":"10.1016\/j.jhepr.2022.100498_bib132","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"New Engl J Med"},{"issue":"9","key":"10.1016\/j.jhepr.2022.100498_bib133","article-title":"Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy","volume":"9","author":"Pinato","year":"2021","journal-title":"J\u00a0ImmunoTherapy Cancer"},{"key":"10.1016\/j.jhepr.2022.100498_bib134","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.705361","article-title":"Immunogenic cell death induction by ionizing radiation","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Immunol"},{"issue":"25","key":"10.1016\/j.jhepr.2022.100498_bib135","doi-asserted-by":"crossref","first-page":"41242","DOI":"10.18632\/oncotarget.17168","article-title":"Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.jhepr.2022.100498_bib136","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/hepr.12789","article-title":"Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma","volume":"47","author":"Friedman","year":"2017","journal-title":"Hepatol Res"},{"issue":"8","key":"10.1016\/j.jhepr.2022.100498_bib137","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: the report of AAPM Task Group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib138","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijrobp.2017.12.290","article-title":"Radiation dose-volume effects for liver SBRT","volume":"110","author":"Miften","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.jhepr.2022.100498_bib139","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clon.2017.09.007","article-title":"UK consensus on normal tissue dose constraints for stereotactic radiotherapy","volume":"30","author":"Hanna","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555922000702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555922000702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:28:26Z","timestamp":1762900106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555922000702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":139,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2589555922000702"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2022.100498","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2022.100498","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100498"}}